Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Matthew H Kulke, M.D.

TitleAssociate Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
D1226
44 Binney St
Boston MA 02115
Phone617/632-5136
Fax617/632-5370

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Christiani DC, Kulke MH. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013; 20(2):187-96.
    View in: PubMed
  2. Kulke MH. Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):75-83.
    View in: PubMed
  3. Kulke MH. Are neuroendocrine tumors going mainstream? J Clin Oncol. 2013 Feb 1; 31(4):404-5.
    View in: PubMed
  4. Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer. 2012 Oct; 19(5):615-23.
    View in: PubMed
  5. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30(24):2963-8.
    View in: PubMed
  6. Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, Rupnick M. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11306-11.
    View in: PubMed
  7. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
    View in: PubMed
  8. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):724-64.
    View in: PubMed
  9. Baez JC, Jagannathan JP, Krajewski K, O'Regan K, Zukotynski K, Kulke M, Ramaiya NH. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012; 12:153-62.
    View in: PubMed
  10. Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, Asomaning K, Ma C, Xu W, Wang Z, Hooshmand S, Su L, Christiani DC, Liu G. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer. 2012 Dec 1; 131(11):2478-86.
    View in: PubMed
  11. Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 2012 Mar; 41(1):119-31.
    View in: PubMed
  12. Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14.
    View in: PubMed
  13. Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. Oncologist. 2012; 17(1):14-e35.
    View in: PubMed
  14. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec; 96(12):3741-9.
    View in: PubMed
  15. Zhai R, Zhao Y, Liu G, Ter-Minassian M, Wu IC, Wang Z, Su L, Asomaning K, Chen F, Kulke MH, Lin X, Heist RS, Wain JC, Christiani DC. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study. Cancer. 2012 Feb 1; 118(3):804-11.
    View in: PubMed
  16. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011; 4:29.
    View in: PubMed
  17. Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol. 2011 Jun; 12(2):136-48.
    View in: PubMed
  18. Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, Frauenhoffer CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH. Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis. 2011 Aug; 32(8):1216-22.
    View in: PubMed
  19. Wu IC, Zhao Y, Zhai R, Liu G, Ter-Minassian M, Asomaning K, Su L, Liu CY, Chen F, Kulke MH, Heist RS, Christiani DC. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia. 2011 Apr; 13(4):386-92.
    View in: PubMed
  20. Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, Kulke M, Baum R. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol. 2011 Jun; 34(3):566-72.
    View in: PubMed
  21. Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist. 2011; 16(3):286-95.
    View in: PubMed
  22. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 1; 29(7):934-43.
    View in: PubMed
  23. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2011 Feb; 18(1):171-80.
    View in: PubMed
  24. Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M, Asomaning K, Su L, Heist RS, Kulke MH, Liu G, Christiani DC. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis. 2011 Apr; 32(4):502-6.
    View in: PubMed
  25. Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol. 2011 Aug; 68(2):293-300.
    View in: PubMed
  26. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug; 39(6):799-800.
    View in: PubMed
  27. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug; 39(6):735-52.
    View in: PubMed
  28. Liu CY, Wu MC, Chen F, Ter-Minassian M, Asomaning K, Zhai R, Wang Z, Su L, Heist RS, Kulke MH, Lin X, Liu G, Christiani DC. A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis. 2010 Jul; 31(7):1259-63.
    View in: PubMed
  29. Kianmanesh R, Ruszniewski P, Rindi G, Kwekkeboom D, Pape UF, Kulke M, Sevilla Garcia I, Scoazec JY, Nilsson O, Fazio N, Lesurtel M, Chen YJ, Eriksson B, Cioppi F, O'Toole D. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010; 91(4):333-40.
    View in: PubMed
  30. Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Wain JC, Christiani DC. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol. 2010 May 10; 28(14):2445-51.
    View in: PubMed
  31. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010 Mar; 34(3):300-13.
    View in: PubMed
  32. Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2010 Oct; 66(5):961-8.
    View in: PubMed
  33. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 1; 28(1):69-76.
    View in: PubMed
  34. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
    View in: PubMed
  35. Kulke MH, Scherübl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S62-6.
    View in: PubMed
  36. Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009 Aug; 19(8):613-25.
    View in: PubMed
  37. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009 Aug 4; 101(3):465-72.
    View in: PubMed
  38. Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47.
    View in: PubMed
  39. Cheung WY, Zhai R, Kulke MH, Heist RS, Asomaning K, Ma C, Wang Z, Su L, Lanuti M, Tanabe KK, Christiani DC, Liu G. Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis. 2009 Aug; 30(8):1363-7.
    View in: PubMed
  40. Chan JA, Kulke MH. Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep. 2009 May; 11(3):193-9.
    View in: PubMed
  41. Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, Wang Z, Kulke M, Su L, Ma C, Xu W, Marshall AL, Heist RS, Wain JC, Lynch TJ, Christiani DC, Liu G. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res. 2009 May 1; 15(9):3103-9.
    View in: PubMed
  42. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 2009 May; 30(5):793-8.
    View in: PubMed
  43. Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, Wain JC, Lynch TJ, Christiani DC. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus. 2010 Jan; 23(1):36-9.
    View in: PubMed
  44. Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80.
    View in: PubMed
  45. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 8; 360(2):195-7.
    View in: PubMed
  46. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 1; 15(1):338-45.
    View in: PubMed
  47. Zhai R, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, Nishioka NS, Lynch TJ, Wain JC, Lin X, Christiani DC. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008 Dec; 29(12):2330-4.
    View in: PubMed
  48. Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4.
    View in: PubMed
  49. Mamon H, Hader C, Li J, Wang L, Kulke M, Amicarelli G, Shehi E, Adlerstein D, Roper K, Killion L, Hooshmand S, Makrigiorgos GM. Preferential amplification of apoptotic DNA from plasma: potential for enhancing detection of minor DNA alterations in circulating DNA. Clin Chem. 2008 Sep; 54(9):1582-4.
    View in: PubMed
  50. Sheehy N, Kulke MH, Van den Abbeele AD. F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma. Clin Nucl Med. 2008 Aug; 33(8):545-6.
    View in: PubMed
  51. Fujiki K, Duerr EM, Kikuchi H, Ng A, Xavier RJ, Mizukami Y, Imamura T, Kulke MH, Chung DC. Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastroenterology. 2008 Sep; 135(3):907-16, 916.e1-2.
    View in: PubMed
  52. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10; 26(20):3403-10.
    View in: PubMed
  53. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer. 2008 Jul; 47(7):591-603.
    View in: PubMed
  54. Kulke MH. Neuroendocrine tumors: is there a standard treatment? Gastrointest Cancer Res. 2008 May; 2(3):152-3.
    View in: PubMed
  55. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008 May; 14(5):579-84.
    View in: PubMed
  56. Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer. 2008 Mar; 15(1):243-56.
    View in: PubMed
  57. Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G. A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):204-11.
    View in: PubMed
  58. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92.
    View in: PubMed
  59. Plöckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology. 2008; 87(1):20-30.
    View in: PubMed
  60. Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007 Sep; 9(4):441-51.
    View in: PubMed
  61. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008 Feb; 53(2):564-70.
    View in: PubMed
  62. Bhargava P, Earle CC, Zhu AX, Clark JW, Vincitore M, Battu S, Regan E, Lawrence C, Kulke MH . A phase II study of pemetrexed in patients (pts) with advanced neuroendocrine tumors (NETs) . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A15149.
  63. Kulke MH, Frauenhoffer CS, Hooshmand SM, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Hornick J, Fuchs C, Redston MS. Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET). . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A4505.
  64. Singh S, Asomaning K, Kulke MH, Zhou W, Zhai R, Su L, Heist RS, Lynch TJ, Christiani DC, Liu G . MMP1 1G/2G promoter polymorphism and risk of esophageal adenocarcinoma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A10555.
  65. Mackay HJ, Bradbury P, Asomaning K, Zhou W, Kulke MH, Su L, Suk Heist R, Lynch TJ, Christiani DC, Liu G. Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS) . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A21047.
  66. Blaszkowsky LS, Ryan DP, Earle C, Kwak E, Fuchs C, Meyerhardt JA, tuart K, Zhu AX, Enzinger P, Kulke MH. A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A15080.
  67. Bradbury PA, Marshall AL, Kulke MH, Zhou W, Heist RS, Su L, Lynch TJ, Shepherd FA, Christiani DC, Liu G. Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer. . Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S):A2511.
  68. Schwarzberg AB, Stover EH, Sengupta T, Michelini A, Vincitore M, Baden LR, Kulke MH. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest. 2007 Jun; 25(4):249-55.
    View in: PubMed
  69. Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr Relat Cancer. 2007 Jun; 14(2):207-19.
    View in: PubMed
  70. Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am. 2007 Jun; 21(3):433-55; vii-viii.
    View in: PubMed
  71. Kulke MH. New developments in the treatment of gastrointestinal neuroendocrine tumors. Curr Oncol Rep. 2007 May; 9(3):177-83.
    View in: PubMed
  72. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs. 2007 May; 12(2):253-70.
    View in: PubMed
  73. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37.
    View in: PubMed
  74. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 1; 24(22):3555-61.
    View in: PubMed
  75. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4283-7.
    View in: PubMed
  76. Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007 Feb; 59(3):285-93.
    View in: PubMed
  77. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 May; 51(5):877-84.
    View in: PubMed
  78. Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 Jun; 51(6):1033-8.
    View in: PubMed
  79. Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg. 2006 Jun; 43(6):383-450.
    View in: PubMed
  80. Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS. A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest. 2006 Jun-Jul; 24(4):346-50.
    View in: PubMed
  81. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. . Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24(No. 18s):A4044.
  82. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006 Apr 20; 24(12):1892-7.
    View in: PubMed
  83. Kulke MH, Wu B, Clark JW, Enzinger PC, Lynch TJ, Vincitore M, Michelini A, Fuchs CS. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest. 2006 Apr-May; 24(3):229-34.
    View in: PubMed
  84. Li J, Wang F, Mamon H, Kulke MH, Harris L, Maher E, Wang L, Makrigiorgos GM. Antiprimer quenching-based real-time PCR and its application to the analysis of clinical cancer samples. Clin Chem. 2006 Apr; 52(4):624-33.
    View in: PubMed
  85. McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle CC, Michelini A, Fuchs CS. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol. 2006 Feb; 29(1):40-4.
    View in: PubMed
  86. Clark OH, Ajani J, Benson AB, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA, Olson JA, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S. Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38.
    View in: PubMed
  87. Li J, Harris L, Mamon H, Kulke MH, Liu WH, Zhu P, Mike Makrigiorgos G. Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma. J Mol Diagn. 2006 Feb; 8(1):22-30.
    View in: PubMed
  88. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006 Jan 20; 24(3):401-6.
    View in: PubMed
  89. Kulke M, Fuchs C. Cancer of the Appendix. Raghavan D, editor. Textbook of the Uncommon Cancer. 2006; 410-417.
  90. Kulke MH, Sommers R, Morgan JA. Role of systemic chemotherapy in the treatment of advanced neuroendocrine tumors. Am J of Hem/Onc. 2006; 5:430-33.
  91. Bello CL, Deprimo SE, Friece C, Smeraglia J, Sherman L, Tye L, Baum CM, Meropol NJ, Lenz H, Kulke MH. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24(18s):A4045.
  92. Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec; 50(12):2218-23.
    View in: PubMed
  93. Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
    View in: PubMed
  94. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6.
    View in: PubMed
  95. Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol. 2005 Sep; 6(5):397-409.
    View in: PubMed
  96. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Baum CM, Fuchs CS. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I of II. 2005; 23(No. 16S):A4008.
  97. Kulke MH. Combination chemotherapy for advanced pancreatic cancer--has its time finally come? Lancet Oncol. 2005 Jun; 6(6):352-3.
    View in: PubMed
  98. Blaszkowsky LS, Kulke MH, Ryan DP, Clark JW, Meyerhardt J, Zhu AX, Lawrence C, Fuchs CS. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Part I of II. 2005; 23(16S ):A4099.
  99. Enzinger PC, Earle C, Zhu A, Blaszkowsky L, Kulke MH, Ryan DP, Michelini A, Langford L, Meyerhardt J. Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced gastrointestinal malignancies. Proc Am Soc Clin Oncol. 2005; A28.
  100. Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul; 10(6):392-8.
    View in: PubMed
  101. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004 Oct; 27(5):485-8.
    View in: PubMed
  102. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, del Monte F, Hajjar RJ, Linke WA. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res. 2004 Oct 1; 95(7):708-16.
    View in: PubMed
  103. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004 Sep 1; 101(5):934-9.
    View in: PubMed
  104. Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke MH, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22(No. 14S):A4040.
  105. Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22(14S):A4011.
  106. Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004 Jun; 127(6):1579-86.
    View in: PubMed
  107. Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004; 22(3):353-9.
    View in: PubMed
  108. Kulke M. Ablative Therapies in Gastrointestinal Malignancies. Van Sonnenberg E and McMullin W, editors. Tumor Ablation: Principles and Practice. 2004; 466-471.
  109. Kulke M, Fuchs C. Clinical Aspects and Management of Small Bowel and Appendiceal Cancers: Management Options - Unresectable, Locally Advanced and Metastatic Small Bowel and Appendiceal Carcinomas. Abruzzese J, editor. Gastrointestinal Oncology. 2004; 585-590.
  110. Kulke M, Mayer R. Management Options: Metastatic Gastric Carcinoma. Abruzzese J, editor. Gastrointestinal Oncology. 2004; 316-325.
  111. Kulke MH. Advanced pancreatic cancer: is there a role for combination therapy? Expert Rev Anticancer Ther. 2003 Oct; 3(5):729-39.
    View in: PubMed
  112. Kulke MH. Neuroendocrine tumours: clinical presentation and management of localized disease. Cancer Treat Rev. 2003 Oct; 29(5):363-70.
    View in: PubMed
  113. Kulke MH. Recent developments in the pharmacological treatment of advanced pancreatic cancer. Expert Opin Investig Drugs. 2003 Jun; 12(6):983-92.
    View in: PubMed
  114. Levine RL, George DJ, Kulke MH. Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. Clin Adv Hematol Oncol. 2003 Feb; 1(2):99-100; discussion 100.
    View in: PubMed
  115. Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4):505-11.
    View in: PubMed
  116. Kulke M. Neuroendocrine Tumors. Furie B, Mayer RJ, Cassileth PA, Atkins MB, editors. Clinical Practice of Hematology and Oncology. 2003; 1113-1138.
  117. Kulke MH. Metastatic pancreatic cancer. Curr Treat Options Oncol. 2002 Dec; 3(6):449-57.
    View in: PubMed
  118. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002 Sep-Oct; 8(5):395-9.
    View in: PubMed
  119. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002 Jun 15; 94(12):3186-91.
    View in: PubMed
  120. Kulke M. Cancer of the Gastrointestinal Tract. Skarin AT, editor. Atlas of Diagnostic Oncology. 2002; 111-160.
  121. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002 Jan 1; 94(1):97-103.
    View in: PubMed
  122. Kulke M. Book Review: Gastrointestinal Oncology: Principles and Practice. N Engl J Med. 2002; 347:1124.
  123. Ellis FH, Xu X, Kulke MH, LoCicero J, Loda M. Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice. J Thorac Cardiovasc Surg. 2001 Oct; 122(4):809-14.
    View in: PubMed
  124. Kulke MH, Thakore KS, Thomas G, Wang H, Loda M, Eng C, Odze RD. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer. 2001 Apr 15; 91(8):1451-7.
    View in: PubMed
  125. Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer. 2001 Mar 23; 84(6):748-53.
    View in: PubMed
  126. Cibas ES, Goss GA, Kulke MH, Demetri GD, Fletcher CD. Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature. Am J Surg Pathol. 2001 Jan; 25(1):121-6.
    View in: PubMed
  127. Kulke MH. The treatment of advanced gastric cancer: in search of the right combination. J Clin Oncol. 2000 Jul; 18(14):2645-7.
    View in: PubMed
  128. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999 Mar 18; 340(11):858-68.
    View in: PubMed
  129. Kulke M, Osteen R, Fuchs C. Cancer of the Appendix. Raghavan D, editor. Textbook of Uncommon Cancer. 1999; 447-455.
  130. Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis. 1997 Aug; 25(2):215-8.
    View in: PubMed
  131. Matthew H Kulke. Isolation of the partial genomic sequence of RHK7 (KV1.7), a novel Shaker-like voltage gated potassium channel. 1992.
  132. Krueger J, Kulke M, Schutt C, Stock J. Protein inclusion body formation and purification. Biopharm. 1989; 40-45.
  133. Matthew H Kulke. Characterization of three point mutants of the CheB methylesterase and a study of their precipitation into inclusion bodies. 1987.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Kulke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (404) concept(s)
_
Co-Authors
See all (89) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_